DE602004013439D1 - Ildung mit 4-hydroxy tamoxifen - Google Patents

Ildung mit 4-hydroxy tamoxifen

Info

Publication number
DE602004013439D1
DE602004013439D1 DE602004013439T DE602004013439T DE602004013439D1 DE 602004013439 D1 DE602004013439 D1 DE 602004013439D1 DE 602004013439 T DE602004013439 T DE 602004013439T DE 602004013439 T DE602004013439 T DE 602004013439T DE 602004013439 D1 DE602004013439 D1 DE 602004013439D1
Authority
DE
Germany
Prior art keywords
hydroxy
tamoxifes
illustration
excessive scarring
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004013439T
Other languages
English (en)
Other versions
DE602004013439T2 (de
Inventor
Andrew R Palumbo
Julius Few
Dana C Hilt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Ascend Therapeutics Inc
Original Assignee
Northwestern University
Ascend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University, Ascend Therapeutics Inc filed Critical Northwestern University
Publication of DE602004013439D1 publication Critical patent/DE602004013439D1/de
Application granted granted Critical
Publication of DE602004013439T2 publication Critical patent/DE602004013439T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602004013439T 2003-06-09 2004-06-02 Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen Expired - Lifetime DE602004013439T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47661803P 2003-06-09 2003-06-09
US476618P 2003-06-09
PCT/EP2004/006583 WO2004110420A1 (en) 2003-06-09 2004-06-02 Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen

Publications (2)

Publication Number Publication Date
DE602004013439D1 true DE602004013439D1 (de) 2008-06-12
DE602004013439T2 DE602004013439T2 (de) 2009-06-04

Family

ID=33551623

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004013439T Expired - Lifetime DE602004013439T2 (de) 2003-06-09 2004-06-02 Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen

Country Status (13)

Country Link
US (1) US7767717B2 (de)
EP (1) EP1631275B1 (de)
JP (1) JP4682129B2 (de)
AT (1) ATE393625T1 (de)
AU (1) AU2004246812B8 (de)
CA (1) CA2528431C (de)
DE (1) DE602004013439T2 (de)
DK (1) DK1631275T3 (de)
ES (1) ES2304610T3 (de)
HK (1) HK1082203A1 (de)
NZ (1) NZ544031A (de)
PT (1) PT1631275E (de)
WO (1) WO2004110420A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE324880T1 (de) * 2002-12-18 2006-06-15 Besins Int Lab Behandlung von mastalgie mit4-hydroxy-tamoxifen
DE60327363D1 (de) 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
ES2456958T3 (es) * 2003-04-01 2014-04-24 Besins Healthcare Luxembourg Sarl Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
MXPA06006834A (es) * 2003-12-15 2006-09-04 Besins Int Lab Uso de 4-hidroxitamoxifen para la preparacion de un medicamento para el tratamiento de ginecomastia.
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579857A1 (de) * 2004-03-22 2005-09-28 Laboratoires Besins International Stabile Zusammensetzungen enthaltend 4-hydroxy Tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (de) * 2004-10-14 2006-04-19 Laboratoires Besins International Gelzubereitung enthaltend 4-Hydroxy tamoxifen.
JP5189093B2 (ja) * 2006-07-31 2013-04-24 ラボラトワール・ベザン・ザンテルナショナル 過剰瘢痕化の治療および予防
EP1891945A1 (de) * 2006-07-31 2008-02-27 Laboratoires Besins International Behandlung und Prävention von übermässiger Narbenbildung
CA2710232A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
US20110130710A1 (en) * 2007-12-21 2011-06-02 David Lawrence Becker Treatment of abnormal or excessive scars
US20140350106A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Urea Silicone Gel for Scars and Hydration Treatment and Method of Using Same
US20140350117A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Topical Scar Treatment Composition and Method of Using Same
WO2019046678A1 (en) * 2017-09-01 2019-03-07 Excel Med, Llc PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CHOLOIDS AND USES THEREOF

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ES2044860T3 (es) * 1987-04-21 1994-01-16 Heumann Pharma Gmbh & Co Estables aductos con disolventes de z-1-(p-beta-di-metil-amino-etoxi-fenil)-1-(p-hidroxi-fenil)-2-fenil-but-1-eno.
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
DE69007486T2 (de) * 1989-07-31 1994-08-11 Massachusetts Institute Of Technology, Cambridge, Mass. Verwendung von calciumantagonisten für die behandlung von narben.
TW218849B (de) 1991-05-17 1994-01-11 Bristol Myers Squibb Co
EP0651637B1 (de) 1992-07-20 2006-10-04 Massachusetts Institute Of Technology Kontrolle der wundvernarbung mit calmodulin-inhibitoren oder protein-kinase-c-inhibitoren
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
EP1043986B1 (de) * 1997-12-23 2003-04-16 Hexal Ag Gemisch und pharmazeutische zubereitung enthaltend z-4-hydroxytamoxifen und cyclodextrin
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1317921B1 (de) * 2001-12-07 2009-08-19 Besins International Belgique Gel oder Lösung enthaltend Dihydrotestosterone, deren Herstellungsverfahren und Verwendung
ATE324880T1 (de) * 2002-12-18 2006-06-15 Besins Int Lab Behandlung von mastalgie mit4-hydroxy-tamoxifen
DE60327363D1 (de) 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
ES2456958T3 (es) * 2003-04-01 2014-04-24 Besins Healthcare Luxembourg Sarl Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (de) 2004-03-22 2005-09-28 Laboratoires Besins International 4-Hydroxytamoxifen zur Behandlung von benignen Brusterkrankungen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579857A1 (de) 2004-03-22 2005-09-28 Laboratoires Besins International Stabile Zusammensetzungen enthaltend 4-hydroxy Tamoxifen
EP1647271A1 (de) * 2004-10-14 2006-04-19 Laboratoires Besins International Gelzubereitung enthaltend 4-Hydroxy tamoxifen.

Also Published As

Publication number Publication date
DE602004013439T2 (de) 2009-06-04
WO2004110420A1 (en) 2004-12-23
AU2004246812B8 (en) 2010-01-14
CA2528431C (en) 2012-09-18
ATE393625T1 (de) 2008-05-15
NZ544031A (en) 2008-08-29
AU2004246812A1 (en) 2004-12-23
EP1631275B1 (de) 2008-04-30
AU2004246812B2 (en) 2009-12-17
HK1082203A1 (en) 2006-06-02
US7767717B2 (en) 2010-08-03
JP4682129B2 (ja) 2011-05-11
US20050032910A1 (en) 2005-02-10
CA2528431A1 (en) 2004-12-23
PT1631275E (pt) 2008-08-04
WO2004110420A8 (en) 2005-11-24
DK1631275T3 (da) 2008-08-18
JP2006527234A (ja) 2006-11-30
ES2304610T3 (es) 2008-10-16
EP1631275A1 (de) 2006-03-08

Similar Documents

Publication Publication Date Title
HK1082203A1 (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
DK1797053T3 (da) Phenothiazinium-forbindelse til sårheling
ATE551996T1 (de) Behandlung oder prävention von diabetes mit cannabidiol
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
BRPI0510925A (pt) métodos e composições para cicatrização de ferida
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
CY1113190T1 (el) Μεθοδος αγωγης της αιμολυτικης νοσου
DE50310516D1 (de) Fredericamycin-derivate
SE0301882D0 (sv) New use I
PT1492561E (pt) Metodo para tratar disturbios da glandula mamaria
CY1113959T1 (el) Χρηση λιποσωματων pvp-ιωδιου για θεραπεια ακμης
ATE475414T1 (de) Tuberkulosebehandlung mit pleuromutilinderivaten
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
BRPI0418589A (pt) composições farmacêuticas e métodos para tratamento por insulina
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
SE0301883D0 (sv) New use II
SE0301884D0 (sv) New use III
SE0301885D0 (sv) New use IV
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
DK1368023T3 (da) Anvendelse af buprenoprphin til behandling af urininkontinens
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft

Legal Events

Date Code Title Description
8364 No opposition during term of opposition